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Abstract 
Objectives. To determine the incidence of Ureaplasma urealyticum (UU) and Ureaplasma 
parvum (UP) in symptomatic and asymptomatic women of reproductive age and to estimate 
antibiotic susceptibility of ureaplasma isolates.  
Material and methods. This study included 424 ureaplasma positive women of 1370 tested 
women who visited gynecological practices during 2010. Cervicovaginal or urethral swab 
specimens from each patient were obtained for cultivation and molecular typing by RT-PCR.  
Results. Ureaplasma spp. was identified by cultivation in 424 (34.4%) cases, of which 79.0% 
were from women with symptoms and 21.0% from women without symptoms. Among 
ureaplasma positive women, 121 (28.5%) were pregnant. Genotyping was successful in 244 
strains, and the majority of samples were identified as UP (92.6%). Among genotyped isolates, 
there were 79.5% from symptomatic and 20.5% from asymptomatic women; 29.9% from 
pregnant and 70.1% from non-pregnant women. There was no difference in the incidence of 
ureaplasma type regarding symptoms. Antibiotic susceptibility of 424 ureaplasma isolates 
identified by cultivation showed that all strains were susceptible to doxycycline, josamycin, 
erythromycin, tetracycline, clarithromycin and pristinamicin, but there was lower susceptibility 
to quinolone antibiotics, i.e. 42.9% and 24.5% isolates were susceptible to ofloxacin and 
ciprofloxacin, respectively.  
Conclusion. This study shows that UP was the most frequent isolated ureaplasma species 
(92.6%). Regarding antibiotic susceptibility, quinolones are not the best choice for treatment of 
ureaplasma infections, while macrolides and tetracyclines are still effective.  
 
Introduction 
Urogenital ureaplasma in women of childbearing age are associated with urethritis, pelvic 
inflammatory disease, pregnancy complications, premature birth and infertility but are also very 
frequent in healthy women. Mycoplasmas are the smallest known free living microorganisms of 
200 to 300 nm in size. Taxonomically, mycoplasmas belong to the class of Mollicutes together 
with ureaplasma, also called T (tiny) mycoplasmas because they produce a very small colony 
size of only 50-60 micrometer in diameter [1]. In humans, urogenital ureaplasma infection is 
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caused by two species, Ureaplasma urealyticum (UU) and Ureaplasma parvum (UP), with a 
total of 14 serotypes. UU has characteristics of biovar T960T (or biovar 2 or A), and includes 10 
large genomic serovars (0.88-1.2 Mbps): 2, 4, 5, 7, 8, 9, 10, 11, 12 and 13, while UP has 
characteristics of parvo biovar (or biovar 1 or B) and includes four serovars: 1, 3, 6 and 14 [2,3].  
In the urogenital system UU and UP are considered pathogenic isolates. In women, the 
urogenital tract infection can be asymptomatic or with mild to severe symptoms, while in men 
ureaplasma commonly causes urethritis. If the infection spreads to the uterus or fallopian tubes in 
women or in the small bowel it may lead to pelvic inflammatory disease. The role of ureaplasma 
in pregnant women is of particular importance as the infection may lead to complications in 
pregnancy resulting in premature labour, miscarriage or stillborn child [2,4–9]. Undiagnosed and 
untreated infection can also lead to infertility. When determining the clinical significance of 
ureaplasma infection, the differentiation of colonization and infection is necessary because of the 
high prevalence of ureaplasmas in the healthy population (ureaplasma 70-80%, mycoplasmas 30-
40%) [10]. The presence of more than 104 CFU in a sample is an additional criterion to 
distinguish colonization from infection. 
Although considered “gold standard”, culture methods could not differentiate species, UU from 
UP. Therefore, it is important to introduce molecular methods such as real-time polymerase 
chain reaction (RT-PCR), which enables distinguishing ureaplasma species [11,12]. The 
objectives of this study were to determine the incidence of UU and UP in symptomatic and 
asymptomatic women of reproductive age and to estimate antibiotic susceptibility of ureaplasma 
isolates. 
 
 
Material and methods 
Study population 
The study was carried out at Gynecological Practices of Primary Health Centers in Zagreb, 
Croatia which are collaborating institutions of the Croatian National Institute of Public Health. 
Of 1370 women who visited gynaecological practices during 2010, 471 women were positive for 
ureaplasma isolates. Only 424 isolates were included in the analysis as for 47 isolates complete 
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medical records were not available. Of the total number of ureaplasma positive women 121 
(28.5%) were pregnant. Women were divided in two groups, 89 (21.0%) asymptomatic women 
who came to the gynaecological examination because of a routine check-up, or disease 
conditions that were not related to urogenital system, and 335 (79.0%) symptomatic women who 
had at least one of the following symptoms: non-specific pain and tension in the lower abdomen, 
increased vaginal discharge, dispareunia, burning and frequent urination. The age of 
symptomatic women ranged from 16 to 64 years (mean 31.6; median 30), while the age of 
asymptomatic women ranged from 20 to 68 years (mean 30.7; median 30).  
Specimen collection 
Cervicovaginal or urethral swab specimens were collected for microbiological and molecular 
analysis. All specimens were obtained before antibiotic treatment. Ureaplasma cultivation  was 
performed at the Department of Bacteriology, while the RT-PCR analysis was performed at the 
Department of Molecular Diagnostics of the Croatian National Institute of Public Health.  
Bacterial detection and antimicrobial susceptibility  
Ureaplasma identification was done by cultivation on agar and liquid medium, as well as with a 
commercial Mycoplasma IST 2 (BioMerieux, Marcy l'Etoile, France). The test is based on the 
principle of metabolic inhibition of sensitive strains. This test allows the cultivation, 
identification, determination of the indicative number of bacteria and determine the susceptibility 
of the isolates to antibiotics [13,14].  
Co-infection with other microorganisms including Gardnerella vaginalis (GV) , beta-haemolytic 
Group B Streptococcus (GBS), Candida albicans  (CA) was identified according to routine 
laboratory methods, including API-tests (BioMérieux SA Marcy l'Etoile, France). Chlamydia 
trachomatis (CT) identification was done with COBAS AMPLICOR CT/NG Test (Roche, Basel, 
Switzerland) and according to Airell et al. [15]. 
Real-time PCR 
Two hundred eighty six samples for which the Mycoplasma IST 2 test result was ≥ 104 CFU 
were used in subsequent identification with RT-PCR. Ureaplasma isolates were stored at -20° C 
until DNA isolation procedure with the commercial assays (QUIamp DNA Mini Kit; QUIAGEN 
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GmbH, Hilden) according to the manufacturer's instructions. Differentiating strains of UU of UP 
was performed as described by Mallard et al. [12].  
Statistical analysis 
Data and statistical analysis was performed in the Division of Molecular Medicine, Rudjer 
Boskovic Institute using GraphPad Prism (version 4.00) (GraphPad Software, San Diego, 
California, USA). Methods of descriptive statistics, Chi square (χ2)-test and Fishers exact test 
were used. The P-values of <0.05 were considered statistically significant.  
Results  
Of the 424 samples, 286 (67.4%) were analyzed by RT-PCR. In 42/286 (14.6%) samples the 
PCR failed to identify ureaplasma species, due to technical difficulties, while 244 samples were 
successfully genotyped (Table 1). There were 18 (7.4%) samples identified as UU and 226 
(92.6%) as UP. Of 18 UU cases, 15 (83.3%) were isolated in symptomatic and three (16.7%) in 
asymptomatic women, while of 226 UP cases 179 (79.2%) and 47 (20.8%) were isolated in 
symptomatic and asymptomatic women, respectively. There were no statistically significant 
difference between the incidence of UU and UP among symptomatic and asymptomatic women 
(P = 0.676).  
In the group of pregnant women, UU and UP were isolated in 4/18 (22.2%) and 69/226 (30.5%) 
women, respectively. In the group of women who were not pregnant, UU was isolated in 14/18 
(77.8%), while UP was isolated in 157/226 (69.5%) women (Table 1). There were no statistically 
significant difference between the incidence of UU and UP among pregnant and non-pregnant 
women (P = 0.459). 
Table 2 presents subgroups of samples including both pregnancy and symptoms data. Statistical 
significance (Chi – square test P = 0.022) was observed in UU and UP isolation in the non-
pregnant subset where UU appeared more often in asymptomatic infections than UP. However, 
this difference is probably due to very limited number of asymptomatic infections in this subset 
(n=6). Using Fishers exact test, which is more suitable for small sample sizes, statistical 
difference was not found (P =0.077) . Subset of samples including only pregnant women did not 
indicate statistically significant difference of ureaplasma species isolation in women with or 
without symptoms (P = 0.138). 
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In a cohort of symptomatic women who were not pregnant, UP was found in 153 of 157 (97.5%) 
cases, while UU in 12 of 14 (85.7%) cases. In a cohort of asymptomatic women who were not 
pregnant, UP was found in 4 of 157 (2.5%) cases, while UU in 2 of 14 (14.3%) cases.    
In a cohort of symptomatic pregnant women UP was found in 26 of 69 (37.7%) cases, while UU 
in 3 of 4 (75.0%) cases.  In asymptomatic pregnant women UP was found in 43 of 69 (62.3%) 
cases, while UU in 1 of 4 (25.0%) cases.  
In genotyped ureaplasma isolates, simultaneously associated microorganisms (Table 3) were GV 
(20.1%), CA (11.1%), GBS(4.1%), and CT (3.7%). However, there was no significant 
differences between UU and UP species in co-isolated microorganisms.  
Antibiotic susceptibility of 424 ureaplasma isolates identified by cultivation (Table 4) showed 
that all strains were sensitive to doxycycline, josamycin, erythromycin, tetracycline, 
clarithromycin, and pristinamicin. Only one ureaplasma isolate showed moderate susceptibility 
to azithromycin. In addition, there was some resistance to quinolone antibiotics.  
The antibiotic susceptibility of 244 ureaplasma genotyped by RT-PCR showed that all strains of 
UU and UP were sensitive to doxycycline, josamycin, erythromycin, tetracycline, clarithromycin 
and pristinamicin even though some isolates were resistant to quinolone antibiotics (Table 4). 
Lower sensitivity was observed to ofloxacin (42.9%) and ciprofloxacin (24.5%). One UU isolate 
(0.3%) showed moderate susceptibility to azithromycin. Regarding genotyped ureaplasma 
isolates, there were 72.2% UU isolates resistant to ciprofloxacin, 
 
Discussion 
In recent years urogenital ureaplasmas are highly frequent isolated in women of childebearing 
age. Prior to this study the prevalence of different ureaplasma species was not well studied for 
the Croatian population. This study showed 34.3% positive samples of urogenital tract in the 
female population. Zdorowska-Stefanov et al. [16] found slightly lower ureaplasma prevalence 
(29.8% of 541 women tested), while Kechagia et al. [17] found slightly higher prevalence 
(37.0% of 369 women tested). Molecular based studies have shown that most of ureaplasma 
isolates thus far considered UU were actually UP [18–20]. According to Kacerovský et al. [21], 
the prevalence of UP in a cohort of healthy women who were not pregnant was 57%, which is a 
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much higher prevalence than those of other genital mycoplasmas, viruses, Chlamydia or GBS 
infections. 
In this study, most ureaplasma isolates were identified as UP (92.6%) as expected [18,21,22]. 
We found no significant differences between UP or UU positive individuals according to 
symptoms or pregnancy. There are evidence of adverse impact of ureaplasma infection on the 
course and outcome of pregnancy [2,4], and that ureaplasma infection in infants is associated 
with low birth weight and perinatal mortality [23]. Govender et al. [24] established ureaplasma 
high prevalence among women aged ≥ 26 years. However, association between colonization of 
Mycoplasma hominis, UU or UP and premature births was not confirmed. Results of this study 
showed that the UU and UP were almost equally often isolated in women who were pregnant or 
not (22.2%; vs. 30.5%).  
Women of reproductive age often suffer from urogenital infections. In this study incidence of 
other concomitant bacteria and fungi with ureaplasma was investigated. Common isolated 
microorganisms with ureaplasma were GV (20.1%), CA (11.1%), GBS (4.1%), and CT (3.7%). 
The results are consistent with a study of Vogel et al. [25] who found GV the most common 
isolate with ureaplasma. In our study CA has been isolated in women with UP (11.9%), but no in 
patients with UU. Since CA causes unpleasant clinical symptoms, we believe that co-infection 
with CA and UP should be investigated in a large number of samples. Despite the significant role 
of CT infection in genitourinary tract, in our study it was found in only 3.7% of women. 
In this study, the antibiotic sensitivity of ureaplasma isolates identified by cultivation showed 
that all strains were sensitive to doxycycline, josamycin, erythromycin, tetracycline, 
clarithromycin and pristinamicin, but some resistance to quinolones was observed. Limited 
sensitivity was observed with ofloxacin (42.9%) and ciprofloxacin (24.5%). One UU (0.3%) 
isolate showed moderate resistance to azithromycin. In addition, regarding the genotyped 
ureaplasma isolates, where 72.2% of UU isolates were resistant to ciprofloxacin, it can be 
concluded that quinolones are not the best choice for treatment of ureaplasma isolates. These 
findings are consistent with research of Baryaktar et al. [23] who estimated higher resistance to 
quinolones of UU, i.e. 86.2% to ofloxacin and 92.6% to ciprofloxacin. The study of Mares et al. 
[26] showing resistance to ofloxacin was 16.1% and 53.8% to ciprofloxacin also support the 
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findings in this study. However, it can be concluded that macrolides and tetracyclines are still 
high effective in ureaplasma infection treating.  
 
Conclusion 
In this study, both species of ureaplasma, UP and UU, appeared in women regardless of 
symptoms or pregnancy with UP being the predominant species in the Croatian population. Due 
to small number of UU samples it is so far impossible to determine differences in pathogenicity 
between UP and UU and further large scale studies should be done to elucidate potential 
differences. 
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Table 1. Ureaplasma genotypes in women according to symptoms and pregnancy status 
 
Ureaplasma isolates 
P value U. urealyticum 
 (n = 18) 
U. parvum  
 (n=226) 
Total 
 (n=244) 
Symptomatic  infection 
Yes 15 (83.3%) 179 (79.2%) 194 (79.5%) 
0.676 
No 3 (16.7%) 47 (20.8%) 50 (20.5%) 
Pregnancy 
Yes 4 (22.2%) 69 (30.5%) 73 (29.9%) 
0.459 
No 14 (77.8%) 157 (69.5%) 171 (70.1%) 
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Table 2. Ureaplasma genotypes in pregnant and non-pregnant women  
 
Ureaplasma isolates 
P value 
U. urealyticum U. parvum Total 
Non-pregnant women 
Symptomatic  
infection 12 (85.7%) 153 (97.5%) 165(96.5%) 
0.077* 
Asymptomatic  
infection 2 (14.3%) 4 (2.5%) 6 (3.5%) 
Subtotal 14 157 171  
Pregnant women 
Symptomatic  
infection  3 (75.0%) 26 (37.7%) 29 (39.7%) 
0.138 
Asymptomatic  
infection  1 (25.0%) 43 (62.3%) 44 (60.3%) 
Subtotal 4 69 73  
* Fishers exact test 
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Table 3. Microorganisms associated with U. parvum and U. urealyticum 
Microorganisms 
Ureaplasma isolates 
U. urealyticum 
 (n = 18) 
U. parvum  
 (n=226) 
Total 
 (n=244) P value 
G. vaginalis 3 (16.7) 46 (20.4) 49 (20.1) 0.707 
C. albicans 0  27 (11.9) 27 (11.1) 0.119 
GBS 1 (5.6) 9 (4.0) 10 (4.1) 0.746 
C. trachomatis 1 (5.6) 8 (3.5) 9 (3.7) 0.662 
Other 
microorganisms* 12 (66.6) 142 (62.8) 154 (63.1) 0.746 
*microorganisms isolated in small numbers and urogenital physiological flora 
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Table 4. Antimicrobial susceptibility of the total isolated ureaplasma and of specific genotype  
Antimicrobial 
agent 
Ureaplasma isolates (N=424) Ureplasma urealyticum (N=18) Ureaplasma parvum (N=226) 
S I R S I R S I R 
Doxycycline 424 (100%) 0 0 18 (100%) 0 0 226 (100%) 0 0 
Josamycin 424 (100%) 0 0 18 (100%) 0 0 226 (100%) 0 0 
Ofloxacin 182 (42.9%) 220 (51.9%) 22 (5.2%) 5 (27.8%) 12 (66.7%) 1 (5.5%) 94 (41.6%) 
122 
(54.0
%) 
10 (4.4%) 
Erythromycin 424 (100%) 0 0 18 (100%) 0 0 226 (100%) 0 0 
Tetracycline 424 (100%) 0 0 18 (100%) 0 0 226 (100%) 0 0 
Ciprofloxacyn 104 (24.5%) 170 (40.1%) 150 (35.4%) 2 (11.1%) 3 (16.7%) 13 (72.2%) 40 (17.7%) 
107 
(47.3
%) 
79 (35.0%) 
Azithromycin 423 (99.7%) 1 (0.3%) 0 17 (99.9%) 1 (0.1%) 0 226 (100%) 0 0 
Clarithromycin 424 (100%) 0 0 18 (100%) 0 0 226 (100%) 0 0 
Pristinamicin 424 (100%) 0 0 18 (100%) 0 0 226 (100%) 0 0 
S, susceptible, I, intermediate, R resistant 
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